3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine

FLEA
Clinical data
Other names	3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine; 3,4-Methylenedioxy-N-methyl-N-hydroxyamphetamine; MDMOH; MDHMA; N-Hydroxy-MDMA
Legal status
Legal status	DE: Anlage I (Authorized scientific use only); UK: Class A;
Identifiers
	IUPAC name 1-(1,3-Benzodioxol-5-yl)-N-hydroxy-N-methylpropan-2-amine;
CAS Number	214414-88-7;
PubChem CID	44350092;
ChemSpider	21106310;
UNII	E2816HU3KT;
KEGG	C22806;
CompTox Dashboard (EPA)	DTXSID90658377 ;
Chemical and physical data
Formula	C11H15NO3
Molar mass	209.245 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=C2C(=CC=C1CC(C)N(C)O)OCO2;
	InChI InChI=1S/C11H15NO3/c1-8(12(2)13)5-9-3-4-10-11(6-9)15-7-14-10/h3-4,6,8,13H,5,7H2,1-2H3; Key:ORADFQZOLNHWRQ-UHFFFAOYSA-N;

FLEA, also known as 3,4-methylenedioxy-N-hydroxy-N-methylamphetamine (MDMOH or MDHMA), is an entactogen, psychedelic, and stimulant of the phenethylamine, amphetamine, and MDxx families. It is the N-hydroxy homologue of MDMA ("Ecstasy"), and the N-methyl homologue of MDOH. FLEA was first synthesized and assayed by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 4–8 hours. He describes FLEA as causing entactogenic and open MDMA-like effects, easing communication, and increasing appreciation of the senses. Shulgin explained the reasoning for naming the compound "FLEA" in PiHKAL.